Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination

• Published in: The Journal of infectious diseases Vol. 228; no. 6; pp. 734 - 741
• Main Authors: Fries, Louis, Formica, Neil, Mallory, Raburn M, Zhou, Haixia, Plested, Joyce S, Kalkeri, Raj, Moldovan, Ioana, Patel, Nita, Albert, Gary, Robinson, Michelle, Cho, Iksung, Chau, Gordon, Dubovsky, Filip, Glenn, Gregory M
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 15.09.2023
• Subjects: CD4 antigen; Clinical trials; Coronaviruses; COVID-19; Cytokines; Immunogenicity; Lymphocytes T; Major; Phenotypes; Placebos; Severe acute respiratory syndrome coronavirus 2; γ-Interferon; COVID-19 vaccine; CD4; variant cross-reactivity; polyfunctional; Matrix-M adjuvant; T-cell response

Abstract Background NVX-CoV2373 is an efficacious coronavirus disease 2019 (COVID-19) vaccine comprising full-length recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (rS) glycoprotein and Matrix-M adjuvant. Phase 2 of a randomized, placebo-controlled, phase 1/2 trial in...